Skip to main content
Top
Published in: Health Research Policy and Systems 1/2013

Open Access 01-12-2013 | Research

Clinical research in Finland in 2002 and 2007: quantity and type

Authors: Elina Hemminki, Jorma Virtanen, Piret Veerus, Elena Regushevskaya

Published in: Health Research Policy and Systems | Issue 1/2013

Login to get access

Abstract

Background

Regardless of worries over clinical research and various initiatives to overcome problems, few quantitative data on the numbers and type of clinical research exist. This article aims to describe the volume and type of clinical research in 2002 and 2007 in Finland.

Methods

The research law in Finland requires all medical research to be submitted to regional ethics committees (RECs). Data from all new projects in 2002 and 2007 were collected from REC files and the characteristics of clinical projects (76% of all submissions) were analyzed.

Results

The number of clinical projects was large, but declining: 794 in 2002 and 762 in 2007. Drug research (mainly trials) represented 29% and 34% of the clinical projects; their total number had not declined, but those without a commercial sponsor had. The number of different principal investigators was large (630 and 581). Most projects were observational, while an experimental design was used in 43% of projects. Multi-center studies were common. In half of the projects, the main funder was health care or was done as unpaid work; 31% had industry funding as the main source. There was a clear difference in the type of research by sponsorship. Industry-funded research was largely drug research, international multi-center studies, with randomized controlled or other experimental design. The findings for the two years were similar, but a university hospital as the main research site became less common between 2002 and 2007.

Conclusions

Clinical research projects were common, but numbers are declining; research was largely funded by health care, with many physicians involved. Drug trials were a minority, even though most research promotion efforts and regulation concerns them.
Literature
1.
go back to reference IOM (Institute of Medicine): Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. 2010, Washington DC: The National Academies Press IOM (Institute of Medicine): Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. 2010, Washington DC: The National Academies Press
2.
go back to reference IOM (Institute of Medicine): Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary. 2011, Washington DC: The National Academies Press IOM (Institute of Medicine): Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary. 2011, Washington DC: The National Academies Press
3.
go back to reference New Pathway for the Regulation and Governance of Health Research. 2011, London: The Academy of Medical Sciences New Pathway for the Regulation and Governance of Health Research. 2011, London: The Academy of Medical Sciences
4.
go back to reference Kramer JM, Smith PB, Califf RM: Impediments to clinical research in the United States. Clin Pharm Ther. 2012, 91: 535-541. 10.1038/clpt.2011.341.CrossRef Kramer JM, Smith PB, Califf RM: Impediments to clinical research in the United States. Clin Pharm Ther. 2012, 91: 535-541. 10.1038/clpt.2011.341.CrossRef
5.
6.
go back to reference European Science Foundation: Investigator-Driven Clinical Trials. Setting Science Agendas for Europe. 2009, Strasbourg: ESF Report European Science Foundation: Investigator-Driven Clinical Trials. Setting Science Agendas for Europe. 2009, Strasbourg: ESF Report
7.
go back to reference European Science Foundation: ESF-EMRC Position Paper: Proposal for a Revision of the “Clinical Trials Directive” (2001/20/EC) and Other Recommendations to Facilitate Clinical Trials. 2011, ESF: Strasbourg European Science Foundation: ESF-EMRC Position Paper: Proposal for a Revision of the “Clinical Trials Directive” (2001/20/EC) and Other Recommendations to Facilitate Clinical Trials. 2011, ESF: Strasbourg
8.
go back to reference Swan J, Robertson M, Evans S: Managing Clinical Research in the UK. 2009, Warwick: Warwick Business School Swan J, Robertson M, Evans S: Managing Clinical Research in the UK. 2009, Warwick: Warwick Business School
10.
go back to reference Patsopoulos NA, Ioannidis JPA, Analatos AA: Origin and funding of most frequently cited papers in medicine: database analysis. BMJ. 2006, 332 (7549): 1061-1064. 10.1136/bmj.38768.420139.80.CrossRefPubMedPubMedCentral Patsopoulos NA, Ioannidis JPA, Analatos AA: Origin and funding of most frequently cited papers in medicine: database analysis. BMJ. 2006, 332 (7549): 1061-1064. 10.1136/bmj.38768.420139.80.CrossRefPubMedPubMedCentral
11.
go back to reference Hemminki E, Piret V, Virtanen J, Juhani L: A qualitative study on clinical research in Finland - fragmented governance and volume in the 2000s. BMJ Open. 2013, 3: 2-CrossRef Hemminki E, Piret V, Virtanen J, Juhani L: A qualitative study on clinical research in Finland - fragmented governance and volume in the 2000s. BMJ Open. 2013, 3: 2-CrossRef
12.
go back to reference Viljamaa K, Lehenkari J, Lemola T, Tuominen T: Tutkimuspolitiikan välineet ja käytännöt – viiden maan vertailu. Suomen Akatemian julkaisuja 2/10. 2010, Suomen Akatemia: Helsinki Viljamaa K, Lehenkari J, Lemola T, Tuominen T: Tutkimuspolitiikan välineet ja käytännöt – viiden maan vertailu. Suomen Akatemian julkaisuja 2/10. 2010, Suomen Akatemia: Helsinki
14.
go back to reference Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A: Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012, 307 (17): 1838-1847. 10.1001/jama.2012.3424.CrossRefPubMed Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A: Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012, 307 (17): 1838-1847. 10.1001/jama.2012.3424.CrossRefPubMed
15.
go back to reference Academy of Finland: Clinical Research in Finland and Sweden. 2009, Helsinki: Publications of the Academy of Finland Academy of Finland: Clinical Research in Finland and Sweden. 2009, Helsinki: Publications of the Academy of Finland
18.
go back to reference Hartmann M: Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials. 2012, 13: 53-10.1186/1745-6215-13-53.CrossRefPubMedPubMedCentral Hartmann M: Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials. 2012, 13: 53-10.1186/1745-6215-13-53.CrossRefPubMedPubMedCentral
19.
go back to reference Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L: Industry sponsorship and research outcome (review). Cochrane Database Syst Rev. 2012, 12: Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L: Industry sponsorship and research outcome (review). Cochrane Database Syst Rev. 2012, 12:
20.
go back to reference Lexchin JR: Implications of pharmaceutical funding on clinical research. Ann Pharmacother. 2005, 39 (1): 194-197.CrossRefPubMed Lexchin JR: Implications of pharmaceutical funding on clinical research. Ann Pharmacother. 2005, 39 (1): 194-197.CrossRefPubMed
21.
go back to reference Avorn J: Torcetrapid and atrovastin – should marketing drive the research agenda?. NJEM. 2005, 352: 2574-2576.CrossRef Avorn J: Torcetrapid and atrovastin – should marketing drive the research agenda?. NJEM. 2005, 352: 2574-2576.CrossRef
22.
go back to reference Den Boer A, Jansen C: Expert Meeting on Publicly Funded Clinical Trials, 22–23 November 2010. 2011, Amsterdam: Wemos Foundation Den Boer A, Jansen C: Expert Meeting on Publicly Funded Clinical Trials, 22–23 November 2010. 2011, Amsterdam: Wemos Foundation
23.
go back to reference Light DW, Lexchin J: Will lower drug prices jeopardize drug research? A policy fact sheet. Am J Bioeth. 2004, 4: W1-W4.CrossRefPubMed Light DW, Lexchin J: Will lower drug prices jeopardize drug research? A policy fact sheet. Am J Bioeth. 2004, 4: W1-W4.CrossRefPubMed
24.
go back to reference Berendt L, Hakansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE: Effect of European clinical trials directive on academic drug trial in Denmark: retrospective study of applications to the Danish medicines agency 1993–2006. BMJ. 2008, 336: 33-35. 10.1136/bmj.39401.470648.BE.CrossRefPubMed Berendt L, Hakansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE: Effect of European clinical trials directive on academic drug trial in Denmark: retrospective study of applications to the Danish medicines agency 1993–2006. BMJ. 2008, 336: 33-35. 10.1136/bmj.39401.470648.BE.CrossRefPubMed
26.
go back to reference Apperely J: Has the European clinical trials directive been a success?. BMJ. 2010, 340: 937-938. 10.1136/bmj.c937.CrossRef Apperely J: Has the European clinical trials directive been a success?. BMJ. 2010, 340: 937-938. 10.1136/bmj.c937.CrossRef
Metadata
Title
Clinical research in Finland in 2002 and 2007: quantity and type
Authors
Elina Hemminki
Jorma Virtanen
Piret Veerus
Elena Regushevskaya
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health Research Policy and Systems / Issue 1/2013
Electronic ISSN: 1478-4505
DOI
https://doi.org/10.1186/1478-4505-11-17

Other articles of this Issue 1/2013

Health Research Policy and Systems 1/2013 Go to the issue